222 related articles for article (PubMed ID: 14766123)
1. Epidermal growth factor receptor: a promising target in solid tumours.
Laskin JJ; Sandler AB
Cancer Treat Rev; 2004 Feb; 30(1):1-17. PubMed ID: 14766123
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future.
Cohenuram M; Saif MW
JOP; 2007 Jan; 8(1):4-15. PubMed ID: 17228128
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective.
Raben D; Helfrich B; Bunn PA
Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):27-38. PubMed ID: 15142632
[TBL] [Abstract][Full Text] [Related]
4. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
Tortora G; Ciardiello F; Gasparini G
Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498
[TBL] [Abstract][Full Text] [Related]
5. Rational bases for the development of EGFR inhibitors for cancer treatment.
Bianco R; Gelardi T; Damiano V; Ciardiello F; Tortora G
Int J Biochem Cell Biol; 2007; 39(7-8):1416-31. PubMed ID: 17596994
[TBL] [Abstract][Full Text] [Related]
6. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
Dassonville O; Bozec A; Fischel JL; Milano G
Crit Rev Oncol Hematol; 2007 Apr; 62(1):53-61. PubMed ID: 17324578
[TBL] [Abstract][Full Text] [Related]
7. Targeting epidermal growth factor receptor in head and neck cancer.
Ford AC; Grandis JR
Head Neck; 2003 Jan; 25(1):67-73. PubMed ID: 12478546
[TBL] [Abstract][Full Text] [Related]
8. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
9. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).
Reid A; Vidal L; Shaw H; de Bono J
Eur J Cancer; 2007 Feb; 43(3):481-9. PubMed ID: 17208435
[TBL] [Abstract][Full Text] [Related]
10. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.
Ciardiello F; Tortora G
Clin Cancer Res; 2001 Oct; 7(10):2958-70. PubMed ID: 11595683
[TBL] [Abstract][Full Text] [Related]
11. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
Pennell NA; Lynch TJ
Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
[TBL] [Abstract][Full Text] [Related]
12. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
Baselga J; Arteaga CL
J Clin Oncol; 2005 Apr; 23(11):2445-59. PubMed ID: 15753456
[TBL] [Abstract][Full Text] [Related]
13. Resistance to epidermal growth factor receptor-targeted therapy.
Morgillo F; Lee HY
Drug Resist Updat; 2005 Oct; 8(5):298-310. PubMed ID: 16172017
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer.
Heymach JV; Nilsson M; Blumenschein G; Papadimitrakopoulou V; Herbst R
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4441s-4445s. PubMed ID: 16857825
[TBL] [Abstract][Full Text] [Related]
15. Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go.
Patel JD; Pasche B; Argiris A
Crit Rev Oncol Hematol; 2004 Jun; 50(3):175-86. PubMed ID: 15182824
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor as a target in cancer therapy.
Kim ES
J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S87-95. PubMed ID: 19795581
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy.
Ang KK; Andratschke NH; Milas L
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):959-65. PubMed ID: 14967456
[TBL] [Abstract][Full Text] [Related]
18. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
19. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.
Tabernero J
Mol Cancer Res; 2007 Mar; 5(3):203-20. PubMed ID: 17374728
[TBL] [Abstract][Full Text] [Related]
20. Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer.
Van Cutsem E
Oncologist; 2006 Oct; 11(9):1010-7. PubMed ID: 17030643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]